Drug Trial Radar · NCT00256204
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Jan 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,174
Actual
Start
Nov 2005
Primary completion
Apr 2008
Study completion Jun 2009
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Nov 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline
Conditions
- Parkinson's Disease
Interventions
Rasagiline MesylateDrug
tablet, 1mg once daily
Rasagiline MesylateDrug
tablet, 2mg once daily
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From BaselineTime frame: 12w, 24w, 36w, 42w, 48w, 54w, 60w, 66w, 72w
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.